I encourage pharmaceutical scientists to become involved in global activities. Because of the pharmaceutical scientists’ skillset, they can provide a way to address medical disparity, improve quality of life in the developing world, and increase longevity

West Lafayette, IN (PRWEB)
August 29, 2019

Prof. Stephen R. Byrn travels to Africa several times a year to teach in the Sustainable Medicines in Africa program, which includes a master’s degree in biotechnology innovation and regulatory science. The next course will take place in Arusha, Tanzania September 2nd through 13th, 2019. Topics to be addressed include Manufacturing, Quality, Regulation, Devices, Harmonization, Innovation, Drug Development, Legal, Control, Lab, Statistics, Audits, Inspections, and INDs.

About 12 years ago, shortly after selling SSCI, Byrn was contacted by Sister Zita Ekeocha of the Medical Missionaries of Mary in Africa. She was teaching industrial pharmacy at the Kilimanjaro School of Pharmacy (KSP) in Moshi, Tanzania, and she was looking for a way to expand the program for her students. Byrn and his wife Sally decided to take some of the funds from the sale of SSCI and used it to help establish the program, working with Purdue University and the KSP. The goal of the program is to enable the manufacture of quality medicines in Africa by Africans. Since its inception, the program has graduated over 100 students and has now expanded to the MS-TCDC, ActionAid Denmark in Arusha, Tanzania, with the support of a grant from the Bill and Melinda Gates Foundation. Some of the profits from Improved Pharma are also used to help support the program in Africa.

For more information on our work in Africa, please visit this link.

Stephen R. Byrn, Ph.D., FAAPS, is the Charles B. Jordan Professor of Medicinal Chemistry for the Department of Industrial and Physical Pharmacy and co-director of the Biotechnology Innovation and Regulatory Science Center at Purdue University. He is also the founder of two pharmaceutical research and information companies, SSCI West Lafayette and Improved Pharma LLC. He currently serves as the Chief Scientific Officer for Improved Pharma, a research and information company dedicated to improving pharmaceutical methods, formulations, and processes. Current research is focused on using synchrotron X-ray powder diffraction to understand the structure of amorphous materials.    

About Improved Pharma

For more information about the techniques discussed in this article or about Improved Pharma’s services, please contact us at 1-765-463-9951 or info@improvedpharma.com.

Share article on social media or email: